RxDoctor Payments Data

Vanessa Charubhumi, MD

Hand Surgery · Bronx, NYNPI 1043669138

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (52.4%), grants and food and beverage — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 62.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $5,074 and has fallen 82.9% since, to $867 in 2025.

$9,546in general payments, 2019–2025

Across 27 payments — averaging $353.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$6K
  • Medical Device Business Services, Inc.$3K
  • Axogen$243
  • Stryker$133
  • Acumed LLC$131
  • Biocircuit Technologies Inc$76
  • plus $52 from 2 others

What the payments were for

  • Grants$2,98431%
  • Food & beverage$1,56216%
  • Education$5,00052%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew14$5,926
Medical Device Business Services, Inc.1$2,984
Axogen2$243
Stryker4$133
Acumed LLC2$131
Biocircuit Technologies Inc1$76
Rock Medical Orthopedics, Inc.2$29
Johnson & Johnson1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,546 in reported general payments places this provider in the 75th percentile of 178 hand surgery providers in New York.

See all hand surgery providers in New York

Medicare billing

Part B allowed, 2024
$31,965
Medicare patients
99
Services billed
1,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium43$1,595
Ibuprofen48$176
Naproxen16$156
Meloxicam27$38
Triamcinolone Acetonide12$22

Paid to pharmacies, not to this prescriber.

Other hand surgery in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →